Contributors All: National vs Global aHUS Research Efforts

The aHUS Alliance shares research within specific nations, and notes the value of a global focus on the collaborative nature of atypical HUS research and of aHUS advocacy. Creating improvements in disease management, determining clinical guidelines, and deepening of the aHUS knowledge base is important within each nation - in turn this benefits global collaboration as it further builds upon such efforts.

Continue ReadingContributors All: National vs Global aHUS Research Efforts

OMS721: Omeros Research Collaboration with University of Cambridge

Pharma News: an Atypical HUS update from the aHUS Alliance. In its 11 December 2018 press release, the Omeros Corporation announced a new collaboration with a UK university to create the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). Focus of the OC3IR will be research into OMS721 and OMS906, but how will it engage other aHUS stakeholders interested in OMS721 clinical trials and atypical HUS advancements in research?

Continue ReadingOMS721: Omeros Research Collaboration with University of Cambridge